BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Feb 07, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Makena hydroxyprogesterone caproate injection regulatory update

FDA granted accelerated approval for an NDA from Hologic for Makena hydroxyprogesterone caproate injection to reduce the risk of preterm delivery before 37 weeks of pregnancy in women with a history of at least 1 spontaneous preterm birth. Under an amended 2008 deal, KV will...

Read the full 204 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >